1. Home
  2. LYEL

as 08-22-2025 4:00pm EST

$
-
-
.
-
-
+
$
-
.
-
-
+
-
.
-
-
%

Stocks

Health Care

Biotechnology: Pharmaceutical Preparations

Nasdaq

Lyell Immunopharma Inc is a clinical-stage cell therapy company. It has a pipeline of product candidates for patients with solid tumors utilizing ex vivo genetic and epigenetic T-cell reprogramming technologies. The company's product pipeline includes, LYL797, LYL119, LYL845 among others.

Founded: 2018 Country:
United States
United States
Employees: N/A City: SOUTH SAN FRANCISCO
Market Cap: 207.7M IPO Year: 2021
Target Price: $15.00 AVG Volume (30 days): 47.2K
Analyst Decision: Sell Number of Analysts: 2
Dividend Yield:
N/A
Dividend Payout Frequency: N/A
EPS: -23.52 EPS Growth: N/A
52 Week Low/High: $7.65 - $32.40 Next Earning Date: 08-12-2025
Revenue: $60,000 Revenue Growth: 11.11%
Revenue Growth (this year): -85.79% Revenue Growth (next year): N/A

LYEL Daily Stock ML Predictions

Share on Social Networks: